Ardelyx (STU:41X) FFO


STU:41X Ardelyx Inc STU:41X
73 GF Score
Price €4.62
GF Value €8.90
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx FFO?

FFO (Funds from operations) only applies to REITs.

STU:41X
73GF Score
Ardelyx Inc STU:41X
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ardelyx (STU:41X) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of €4.62 is trading 48.1% below its estimated GF Value™ of €8.90. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for STU:41X:

  • FFO:
  • GF Value™: €8.90 vs. price of €4.62 (48.1% below fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the STU:41X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ardelyx Business Description

Other Exchanges ARDX:USAARDX:Mexico
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
73GF Score

Get the complete analysis for STU:41X

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.62
Price
€8.90
GF Value